(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Apellis Pharmaceuticals's revenue in 2023 is $272,877,000.On average, 8 Wall Street analysts forecast APLS's revenue for 2023 to be $44,040,623,059, with the lowest APLS revenue forecast at $39,910,781,476, and the highest APLS revenue forecast at $46,681,631,333. On average, 8 Wall Street analysts forecast APLS's revenue for 2024 to be $78,570,440,533, with the lowest APLS revenue forecast at $47,328,878,033, and the highest APLS revenue forecast at $103,029,895,680.
In 2025, APLS is forecast to generate $124,680,902,131 in revenue, with the lowest revenue forecast at $92,687,101,981 and the highest revenue forecast at $153,949,440,547.